- Priced for perfection, investors were getting scared by a restricted cash issue and a downward revenue guidance, and the shares fell almost 50%.
- On closer inspection we don’t think these scares are all that scary so we opened up a position for the SHU portfolio.
- The shares are still not cheap and they are rather volatile, but there are few companies with the metrics of PaySign, boasting 50%+ revenue growth and triple digit profit growth.
- We think the good times can last for quite a while, given the rate of their pharma market penetration and the upcoming Premier Card.
PaySign Had A Scare, And We Took Advantage
September 20th, 2019 · No Comments